In 1998 and 1999, Chopra, along with two co-workers, Margaret Haydon and Gerard Lambert, testified to the
Senate of Canada's
Standing Committee on Agriculture and Forestry that they were pressured by senior supervisors to approve multiple drugs of questionable safety, including
Bovine Growth Hormone (rBST) and
Baytril, which in the words of Chopra, "is even more controversial. It's a critical antibiotic, one that produces cross-resistance against a critical antibiotic necessary for human use called
ciprofloxacin. It's from the same class of drugs. When it is used in poultry, beef, turkeys, pigs, or whatever, then it causes cross-resistance in the intestines of those animals. Then those bacteria, like
Salmonella,
Campylobacter, or
E. coli, get transferred to people and cause disease and death of immense order." Prior to the
mad cow disease crisis in Canada, Chopra warned the government that the current handling of feed to
cows was inadequate. Following this, Chopra, Haydon, Lambert and colleague Chris Bassude complained to the Public Service Integrity Officer (PSIO) office, a federal investigative body under the jurisdiction of the
Treasury Board of Canada, indicating again that they were pressured by their seniors to pass a number of veterinary drugs, including
Tylosin,
Revalor H, Synergistin Injectable Suspension,
Baytril, rBST, Carbodex and Eugenol, without proof of human safety. The PSIO case was initially dismissed in 2003, but the ruling was appealed to the
Federal Court of Canada. In June 2004, Chopra, Haydon and Lambert were fired from Health Canada. Chopra's letter revealed that the stated reason for his dismissal was his "total lack of progress" in a current project. As of 2009 it appears that the PSIO or its successors has still not issued a new ruling on the case, although Chopra's case is mentioned in a history of managing in ethics in public service issued by the human resources office of Canada's Treasury Secretariat (which oversees the PSIO). ==Human rights complaint==